1100767-21-2

Upstream product

• 2033-24-1 cycl-isopropylidene malonate 
• 873-74-5 4-Aminobenzonitrile 
• 113117-17-2 ethyl 3-[(4-cyanophenyl)amino]-3-oxopropanoate 

Downstream Products

• 1100767-43-8 5-(2-bromo-4-{1-[2-(4-carbamimidoyl-phenylcarbamoyl)-acetylamino]-ethyl}-phenoxy)-nicotinic acid trifluoroacetate 
• 1100767-30-3 5-(2-bromo-4-{(S)-1-[2-(4-carbamimidoyl-phenylcarbamoyl)-acetylamino]-ethyl}-phenoxy)-nicotinic acid acetate 
• 1100767-40-5 5-[2-bromo-4-(1-{2-[4-(N-hydroxycarbamimidoyl)-phenylcarbamoyl]-acetylamino}-ethyl)-phenoxy]-nicotinic acid hydrochloride 
• 1100767-38-1 methyl-5-[2-bromo-4-(1-{2-[4-(N-hydroxycarbamimidoyl)-phenylcarbamoyl]-acetylamino}-ethyl)-phenoxy]-nicotinate 
• 1436685-44-7 5-(4-cyanobenzyl)-7-hydroxy-N-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1436685-40-3 5-(4-cyanobenzyl)-N-(4-fluorophenyl)-7-hydroxypyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1100767-36-9 methyl-5-(2-bromo-4-{1-[2-(4-cyano-phenylcarbamoyl)-acetylamino]-ethyl}-phenoxy)-nicotinate 

Relevant academic research and scientific papers

MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY

The present invention relates to compounds of the formula (I). The compounds of the formula (I) are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are inhibitors of the blood clotting enzymes, especially factor VIla and can in general be applied in conditions in which an undesired activity of factor VIla is present or for the cure or prevention of which an inhibition of factor VIla is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

Acetic acid derivatives

Acetic acid derivatives of the formula STR1 wherein L, M, T and Q have the significance given in the description, can be used for the treatment or prophylaxis of illnesses which are caused by the binding of adhesive proteins to blood platelets and by blood platelet aggregation and cell-cell adhesion, and are manufactured by cleaving protecting groups in the corresponding protected compounds or by converting the cyano group into the amidino group in corresponding nitriles.